Malignant Mesothelioma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Malignant Mesothelioma – Pipeline Review, H2 2017’, provides an overview of the Malignant Mesothelioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Malignant Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma

The report reviews pipeline therapeutics for Malignant Mesothelioma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Malignant Mesothelioma therapeutics and enlists all their major and minor projects

The report assesses Malignant Mesothelioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Malignant Mesothelioma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aduro BioTech Inc

Advantagene Inc

AnGes MG Inc

arGEN-X BV

ArQule Inc

AVEO Pharmaceuticals Inc

Biogen Inc

Bionomics Ltd

Biotecnol Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CanBas Co Ltd

CBT Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Concordia International Corp

Eagle Pharmaceuticals Inc

Eli Lilly and Company

EnGeneIC Ltd

EpiZyme Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Genelux Corp

GlaxoSmithKline Plc

Horizon Pharma Plc

Inventiva

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Laboratoires Pierre Fabre SA

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

MolMed SpA

Morphotek Inc

MTG Biotherapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

OSE Immunotherapeutics

Oxford BioMedica Plc

Pharma Mar SA

Philogen SpA

Polaris Pharmaceuticals Inc

Seattle Genetics Inc

Selecta Biosciences Inc

Sorrento Therapeutics Inc

Targovax ASA

Tesaro Inc

TRACON Pharmaceuticals Inc

TREAT U SA

UbiVac LLC

VasGene Therapeutics Inc

Verastem Inc

Vyriad Inc

Y's Therapeutics Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Malignant Mesothelioma - Overview 6

Malignant Mesothelioma - Therapeutics Development 7

Malignant Mesothelioma - Therapeutics Assessment 20

Malignant Mesothelioma - Companies Involved in Therapeutics Development 33

Malignant Mesothelioma - Drug Profiles 60

Malignant Mesothelioma - Dormant Projects 521

Malignant Mesothelioma - Discontinued Products 523

Malignant Mesothelioma - Product Development Milestones 524

Appendix 536

List of Tables

List of Tables

Number of Products under Development for Malignant Mesothelioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Malignant Mesothelioma – Pipeline by Aduro BioTech Inc, H2 2017

Malignant Mesothelioma – Pipeline by Advantagene Inc, H2 2017

Malignant Mesothelioma – Pipeline by AnGes MG Inc, H2 2017

Malignant Mesothelioma – Pipeline by arGEN-X BV, H2 2017

Malignant Mesothelioma – Pipeline by ArQule Inc, H2 2017

Malignant Mesothelioma – Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma – Pipeline by Biogen Inc, H2 2017

Malignant Mesothelioma – Pipeline by Bionomics Ltd, H2 2017

Malignant Mesothelioma – Pipeline by Biotecnol Ltd, H2 2017

Malignant Mesothelioma – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Malignant Mesothelioma – Pipeline by Boston Biomedical Inc, H2 2017

Malignant Mesothelioma – Pipeline by Bristol-Myers Squibb Company, H2 2017

Malignant Mesothelioma – Pipeline by Calithera Biosciences Inc, H2 2017

Malignant Mesothelioma – Pipeline by CanBas Co Ltd, H2 2017

Malignant Mesothelioma – Pipeline by CBT Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma – Pipeline by Checkpoint Therapeutics Inc, H2 2017

Malignant Mesothelioma – Pipeline by Concordia International Corp, H2 2017

Malignant Mesothelioma – Pipeline by Eagle Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma – Pipeline by Eli Lilly and Company, H2 2017

Malignant Mesothelioma – Pipeline by EnGeneIC Ltd, H2 2017

Malignant Mesothelioma – Pipeline by EpiZyme Inc, H2 2017

Malignant Mesothelioma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Malignant Mesothelioma – Pipeline by Five Prime Therapeutics Inc, H2 2017

Malignant Mesothelioma – Pipeline by Genelux Corp, H2 2017

Malignant Mesothelioma – Pipeline by GlaxoSmithKline Plc, H2 2017

Malignant Mesothelioma – Pipeline by Horizon Pharma Plc, H2 2017

Malignant Mesothelioma – Pipeline by Inventiva, H2 2017

Malignant Mesothelioma – Pipeline by Juno Therapeutics Inc, H2 2017

Malignant Mesothelioma – Pipeline by Karyopharm Therapeutics Inc, H2 2017

Malignant Mesothelioma – Pipeline by Laboratoires Pierre Fabre SA, H2 2017

Malignant Mesothelioma – Pipeline by MacroGenics Inc, H2 2017

Malignant Mesothelioma – Pipeline by Madrigal Pharmaceuticals Inc., H2 2017

Malignant Mesothelioma – Pipeline by MedImmune LLC, H2 2017

Malignant Mesothelioma – Pipeline by Merck & Co Inc, H2 2017

Malignant Mesothelioma – Pipeline by Merck KGaA, H2 2017

Malignant Mesothelioma – Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma – Pipeline by MolMed SpA, H2 2017

Malignant Mesothelioma – Pipeline by Morphotek Inc, H2 2017

Malignant Mesothelioma – Pipeline by MTG Biotherapeutics Inc, H2 2017

Malignant Mesothelioma – Pipeline by Novartis AG, H2 2017

Malignant Mesothelioma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Malignant Mesothelioma – Pipeline by OSE Immunotherapeutics, H2 2017

Malignant Mesothelioma – Pipeline by Oxford BioMedica Plc, H2 2017

Malignant Mesothelioma – Pipeline by Pharma Mar SA, H2 2017

Malignant Mesothelioma – Pipeline by Philogen SpA, H2 2017

Malignant Mesothelioma – Pipeline by Polaris Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma – Pipeline by Seattle Genetics Inc, H2 2017

Malignant Mesothelioma – Pipeline by Selecta Biosciences Inc, H2 2017

Malignant Mesothelioma – Pipeline by Sorrento Therapeutics Inc, H2 2017

Malignant Mesothelioma – Pipeline by Targovax ASA, H2 2017

Malignant Mesothelioma – Pipeline by Tesaro Inc, H2 2017

Malignant Mesothelioma – Pipeline by TRACON Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma – Pipeline by TREAT U SA, H2 2017

Malignant Mesothelioma – Pipeline by UbiVac LLC, H2 2017

Malignant Mesothelioma – Pipeline by VasGene Therapeutics Inc, H2 2017

Malignant Mesothelioma – Pipeline by Verastem Inc, H2 2017

Malignant Mesothelioma – Pipeline by Vyriad Inc, H2 2017

Malignant Mesothelioma – Pipeline by Y's Therapeutics Co Ltd, H2 2017

Malignant Mesothelioma – Dormant Projects, H2 2017

Malignant Mesothelioma – Dormant Projects, H2 2017 (Contd..1), H2 2017

Malignant Mesothelioma – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Malignant Mesothelioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports